[1] Berenbaum F, Walker C. Osteoarthritis and inflammation: a serious disease with overlapping phenotypic patterns. Postgrad Med. 2020 : 1-8.
[2] Kloppenburg M, Berenbaum F. Osteoarthritis year in review 2019: epidemiology and therapy. Osteoarthritis Cartilage. 2020. 28(3): 242-248.
[3] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018. 392(10159): 1789-1858.
[4] Mendy A, Park J, Vieira ER. Osteoarthritis and risk of mortality in the USA: a population-based cohort study. Int J Epidemiol. 2018. 47(6): 1821-1829.
[5] Silawal S, Willauschus M, Schulze-Tanzil G, Gögele C, Geßlein M, Schwarz S. IL-10 Could Play a Role in the Interrelation between Diabetes Mellitus and Osteoarthritis. Int J Mol Sci. 2019. 20(3).
[6] Veronese N, Cooper C, Reginster JY, et al. Type 2 diabetes mellitus and osteoarthritis. Semin Arthritis Rheum. 2019. 49(1): 9-19.
[7] Rogers-Soeder TS, Lane NE, Walimbe M, et al. Association of Diabetes Mellitus and Biomarkers of Abnormal Glucose Metabolism With Incident Radiographic Knee Osteoarthritis. Arthritis Care Res (Hoboken). 2020. 72(1): 98-106.
[8] Alenazi AM, Alshehri MM, Alothman S, et al. The Association of Diabetes with Knee Pain Severity and Distribution in People with Knee Osteoarthritis using Data from the Osteoarthritis Initiative. Sci Rep. 2020. 10(1): 3985.
[9] WAINE H, NEVINNY D, ROSENTHAL J, JOFFE IB. Association of osteoarthritis and diabetes mellitus. Tufts Folia Med. 1961. 7: 13-9.
[10] Berenbaum F. Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype. Ann Rheum Dis. 2011. 70(8): 1354-6.
[11] Barbour KE, Helmick CG, Boring M, Brady TJ. Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2013-2015. MMWR Morb Mortal Wkly Rep. 2017. 66(9): 246-253.
[12] Schett G, Kleyer A, Perricone C, et al. Diabetes is an independent predictor for severe osteoarthritis: results from a longitudinal cohort study. Diabetes Care. 2013. 36(2): 403-9.
[13] Reiser KM. Nonenzymatic glycation of collagen in aging and diabetes. Proc Soc Exp Biol Med. 1998. 218(1): 23-37.
[14] Schmidt AM, Yan SD, Stern DM. The dark side of glucose. Nat Med. 1995. 1(10): 1002-4.
[15] Ma C, Zhang Y, Li YQ, Chen C, Cai W, Zeng YL. The Role of PPARgamma in Advanced Glycation End Products-Induced Inflammatory Response in Human Chondrocytes. PLoS One. 2015. 10(5): e0125776.
[16] Chen C, Ma C, Zhang Y, Zeng Y, Li Y, Wang W. Pioglitazone inhibits advanced glycation end product-induced TNF-alpha and MMP-13 expression via the antagonism of NF-kappaB activation in chondrocytes. Pharmacology. 2014. 94(5-6): 265-72.
[17] Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994. 79(7): 1147-56.
[18] Li Y, Zhang Y, Chen C, Zhang H, Ma C, Xia Y. Establishment of a rabbit model to study the influence of advanced glycation end products accumulation on osteoarthritis and the protective effect of pioglitazone. Osteoarthritis Cartilage. 2015 .
[19] Tenconi PE, Bermúdez V, Oresti GM, Giusto NM, Salvador GA, Mateos MV. High glucose-induced phospholipase D activity in retinal pigment epithelium cells: New insights into the molecular mechanisms of diabetic retinopathy. Exp Eye Res. 2019. 184: 243-257.
[20] Paolillo FR, Mattos VS, Borghi-Silva A, Bagnato VS, de Castro Neto JC. Advanced Glycation Endproducts as Biomarkers for Risk of Diabetes and Cardiovascular Diseases by Skin Autofluorescence: A Noninvasive Optical Screening. Photobiomodul Photomed Laser Surg. 2019. 37(3): 168-174.
[21] Gillery P. [Oxidative stress and protein glycation in diabetes mellitus]. Ann Biol Clin (Paris). 2006. 64(4): 309-14.
[22] Yang Q, Chen C, Wu S, Zhang Y, Mao X, Wang W. Advanced glycation end products downregulates peroxisome proliferator-activated receptor gamma expression in cultured rabbit chondrocyte through MAPK pathway. Eur J Pharmacol. 2010. 649(1-3): 108-14.
[23] Zhang HB, Zhang Y, Chen C, Li YQ, Ma C, Wang ZJ. Pioglitazone inhibits advanced glycation end product-induced matrix metalloproteinases and apoptosis by suppressing the activation of MAPK and NF-κB. Apoptosis. 2016. 21(10): 1082-93.
[24] Mobasheri A, Neama G, Bell S, Richardson S, Carter SD. Human articular chondrocytes express three facilitative glucose transporter isoforms: GLUT1, GLUT3 and GLUT9. Cell Biol Int. 2002. 26(3): 297-300.
[25] Courties A, Sellam J. Osteoarthritis and type 2 diabetes mellitus: What are the links. Diabetes Res Clin Pract. 2016. 122: 198-206.
[26] Chen YJ, Chan DC, Lan KC, et al. PPARgamma is involved in the hyperglycemia-induced inflammatory responses and collagen degradation in human chondrocytes and diabetic mouse cartilages. J Orthop Res. 2015. 33(3): 373-81.
[27] Liang H, Wang H, Luo L, et al. Toll-like receptor 4 promotes high glucose-induced catabolic and inflammatory responses in chondrocytes in an NF-κB-dependent manner. Life Sci. 2019. 228: 258-265.
[28] Cho MC, Lee K, Paik SG, Yoon DY. Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res. 2008. 2008: 679137.
[29] Szanto A, Nagy L. The many faces of PPARgamma: anti-inflammatory by any means. Immunobiology. 2008. 213(9-10): 789-803.
[30] Kobayashi T, Notoya K, Naito T, et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. Arthritis Rheum. 2005. 52(2): 479-87.
[31] Boileau C, Martel-Pelletier J, Fahmi H, Mineau F, Boily M, Pelletier JP. The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. Arthritis Rheum. 2007. 56(7): 2288-98.
[32] Vasheghani F, Monemdjou R, Fahmi H, et al. Adult cartilage-specific peroxisome proliferator-activated receptor gamma knockout mice exhibit the spontaneous osteoarthritis phenotype. Am J Pathol. 2013. 182(4): 1099-106.
[33] Ishibashi Y, Matsui T, Ohta K, et al. PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation. Microvasc Res. 2013. 85: 54-8.
[34] Li F, Cai Z, Chen F, et al. Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products. Basic Res Cardiol. 2012. 107(6): 306.
[35] Puddu A, Sanguineti R, Durante A, Viviani GL. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012. 177(1-3): 79-84.
[36] Yuan X, Liu N. Pioglitazone suppresses advanced glycation end product-induced expression of plasminogen activator inhibitor-1 in vascular smooth muscle cells. J Genet Genomics. 2011. 38(5): 193-200.
[37] Zhang Y, Luo Z, Ma L, Xu Q, Yang Q, Si L. Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor gamma activation. Int J Mol Med. 2010. 25(5): 729-34.
[38] Liang C, Ren Y, Tan H, et al. Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products. Br J Pharmacol. 2009. 158(8): 1865-73.
[39] Yamagishi S, Nakamura K, Matsui T. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Pharmacol Res. 2009. 60(3): 174-8.
[40] Lin J, Tang Y, Kang Q, Feng Y, Chen A. Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARgamma activity and attenuating oxidative stress. Br J Pharmacol. 2012. 166(8): 2212-27.
[41] Jiang LY, Tang SS, Wang XY, et al. PPARgamma agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus. CNS Neurosci Ther. 2012. 18(8): 659-66.
[42] Chen YJ, Sheu ML, Tsai KS, Yang RS, Liu SH. Advanced glycation end products induce peroxisome proliferator-activated receptor gamma down-regulation-related inflammatory signals in human chondrocytes via Toll-like receptor-4 and receptor for advanced glycation end products. PLoS One. 2013. 8(6): e66611.